Home » AstraZeneca investors raise concerns over mega-merger talks

AstraZeneca investors raise concerns over mega-merger talks

AstraZeneca investors raise concerns over mega-merger talks

This post was originally published on this site.

Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb